W. Bryan Hubbard Advocates for Ibogaine Research in Opioid Addiction Treatment

W. Bryan Hubbard, an advocate for the use of psychedelic drugs, particularly ibogaine, believes these substances can aid in addressing opioid addiction and other mental health issues. He recently met at Trinity United Methodist Church in Denver to discuss his efforts in promoting ibogaine, which has been linked to potential benefits for treating opioid withdrawal and PTSD, despite limited clinical data. In April 2026, President Donald Trump signed an executive order to expedite research on psychedelics, including ibogaine, as treatments for mental health conditions. Hubbard's advocacy has gained traction among conservative circles, reflecting a shift in the political landscape regarding psychedelics. He aims to allocate 5% of Kentucky's opioid-settlement funds for ibogaine research but faced challenges due to political changes. Hubbard co-founded a nonprofit, Americans for Ibogaine, to further promote research and legislation supporting ibogaine. While some researchers express caution regarding the promotion of psychedelics, Hubbard remains committed to advocating for their potential benefits.